Drug combination with golidocitinib for NK/T-cell lymphoma with HLH
Tests a drug mix including golidocitinib for NK/T-cell lymphoma with HLH.
Key facts
- Who runs it
- Beijing Tongren Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 25 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional
- Treatments tested
- Mitoxantrone liposome
- Etoposide
- Pegaspargase (PEG) Asparaginase
- methylprednisolone
- golidocitinib
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extranodal NK/T-cell lymphoma that has caused hemophagocytic lymphohistiocytosis (HLH), a severe over-reaction of the immune system.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Extranodal NK/T-cell lymphoma confirmed by tissue test, with HLH meeting at least 5 of the HLH-2004 criteria.
- Biomarker or test result
- HIV test must be negative. HCV antibody negative, or positive with negative HCV RNA. HBsAg and HBcAb negative; if either is positive, HBV DNA must be < 1×10³ copies/mL. Heart pumping strength (LVEF) must be ≥ 50%.
Main reasons for not taking part
- Heart failure of NYHA class II or higher
- Pregnant or breastfeeding
- Lymphoma spread to the brain or spinal cord, or another cancer (except non-melanoma skin cancer)
- Active internal bleeding or uncontrolled infection
- Severe kidney problems (filtration rate < 15 mL/min), severe cirrhosis (MELD score > 20), or past pancreatitis
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Histologically confirmed extranodal NK/T-cell lymphoma
- Meeting the HLH-2004 diagnostic criteria (≥ 5 criteria)
- Age ≥ 18 years, regardless of gender
- Negative HIV antigen or antibody
- Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac echocardiography
- No active visceral bleeding (e.g., gastrointestinal, pulmonary, cerebral)
- No uncontrolled infection (e.g., pulmonary infection, intestinal infection)
- Negative HCV antibody; or positive HCV antibody with negative HCV RNA
- Negative HBsAg and negative HBcAb. If either is positive, peripheral blood HBV DNA load must be < 1×10³ copies/mL to be eligible
- Signed written informed consent and ability to understand and comply with all study requirements
Who cannot take part
- Presence of other concurrent malignancies (except non-melanoma skin cancer)
- Concurrent central nervous system lymphoma infiltration
- New York Heart Association (NYHA) cardiac function class ≥ II
- Known hypersensitivity to any of the study drugs
- Severe psychiatric disorders or inability to comply with follow-up
- History of acute or chronic pancreatitis
- Female patients who are pregnant or breastfeeding
- Severe renal dysfunction (glomerular filtration rate < 15 mL/min)
- Severe liver cirrhosis (MELD score > 20)
- Simultaneous participation in another clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patients develop secondary hemophagocytic lymphohistiocytosis (NKTCL-HLH), a life-threatening complication with median survival <2 months and mortality over 90%. Current treatments fail to simultaneously control lymphoma and hyperinflammation, with poor tolerance and high resistance.
Read full original descriptionShow less
The JAK/STAT pathway drives EBV-induced inflammation and tumor progression. Golidocitinib, a selective JAK1 inhibitor, demonstrates potent anti-NKTCL activity and rapid inflammation control. Liposomal mitoxantrone offers targeted efficacy with lower toxicity, while etoposide, methylprednisolone, and pegaspargase provide synergistic anti-tumor and anti-HLH effects.
This study proposes the novel MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH. By targeting both HLH and NKTCL, this combination aims to achieve rapid disease control, improve tolerance, and prolong survival, addressing the unmet critical clinical need for this high-risk population.
The group in the trial
- MEPL-G groupTreatment being tested
All enrolled patients may initiate induction therapy with the MEPL-G regimen after completing baseline imaging and laboratory examinations. The detailed administration is as follows: Doses of etoposide, golidocitinib, pegaspargase, and methylprednisolone are fixed. The optimal dose of liposomal mitoxantrone will be determined based on dose-limiting toxicity (DLT). In the Phase Ib part, 3 patients will be enrolled at the starting dose of liposomal mitoxantrone: 18 mg/m²/d on day 1, every 3 weeks (q3w). If no DLT occurs, the recommended phase 2 dose (RP2D) will be 18 mg/m²/d on day 1 q3w. If DLT occurs, the dose will be de-escalated sequentially. One cycle is 3 weeks, for a total of 6 cycles. Patients achieving CR or PR after 2 cycles may be referred for allogeneic hematopoietic stem cell transplantation. Patients with CR or PR after 2 cycles who are ineligible for transplantation may continue MEPL-G for a total of 6 cycles, followed by maintenance therapy with golidocitinib monotherapy
Treatment: Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase, methylprednisolone, and golidocitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH): a Prospective, Multi-center, Single Arm, Phase Ib/II Clinical Trial
- Plain-language title
- Drug combination with golidocitinib for NK/T-cell lymphoma with HLHGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 13 April 2026